Register for free to
view the full innovation profile.
Use of activin-like kinase inhibitors for the treatment of obesity and obesity-related pathologies.
About
Background: Use of Activin Like Kinase Inhibitors for the Treatment of Obesity and Obesity-Related Pathologies BYU professors have discovered that SGI-1252 blocks TGFbeta signaling. THis mitigates activation of downstream mediators, thus increasing production of genes involved in the thermogenic processes. This process is involved in conversion from white to brown adipocytes, which in turn increase 'wasting', or in other words converting lipids into heat. As a result of the studies, the animals treates with SGI-1252 are leaner, and as a result the drug can be used in the treatment of obesity and obesity related diseases. About the Market: This bioactive compound has aleady had some regulatory review for another diseas indication. The inventors would like to discuss a partnering arangement to help develop the drug for these two important indications.